Preferred Label : lorlatinib;
CISMeF synonym : 7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile;
MeSH synonym : loratinib; (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile;
MeSH hyponym : PF06463922;
UNII : OSP71S83EU;
Origin ID : C000590786;
UMLS CUI : C4080091;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3382736/fr/lorviqua-lorlatinib
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
lorlatinib
administration, oral
adult
protein kinase inhibitors
antineoplastic agents
carcinoma, non-small-cell lung
Advanced Lung Non-Small Cell Carcinoma
ALK Positive
evaluation of the transparency committee
lorlatinib
---
https://www.has-sante.fr/jcms/p_3349484/fr/lorviqua-lorlatinib-cancer-du-poumon-non-a-petites-cellules
2022
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
administration, oral
lorlatinib
lorlatinib
carcinoma, non-small-cell lung
disease progression
Refractory Lung Non-Small Cell Carcinoma
Advanced Lung Non-Small Cell Carcinoma
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/lorbrena-cancer-poumon-4943.html
2020
false
false
false
Canada
French
drug evaluation
carcinoma, non-small-cell lung
lorlatinib
ALK Positive
neoplasm metastasis
protein kinase inhibitors
Anaplastic Lymphoma Kinase
adult
administration, oral
Tyrosine Kinase Inhibitors
lorlatinib
lactams, macrocyclic
---
https://www.has-sante.fr/jcms/p_3146314/fr/lorviqua
2020
false
false
false
France
treatment outcome
carcinoma, non-small-cell lung
lorlatinib
administration, oral
antineoplastic agents
protein kinase inhibitors
Anaplastic Lymphoma Kinase
evaluation of the transparency committee
lorlatinib
lactams, macrocyclic
---
https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
administration, oral
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
lung neoplasms
carcinoma, non-small-cell lung
adult
drug interactions
pregnancy
breast feeding
lorlatinib
drug evaluation, preclinical
lorlatinib
lorlatinib
lactams, macrocyclic
lactams, macrocyclic
---